Genenta to Appoint Richard Slansky as CFO and Anthony Marucci as Board Member

By Dr. Matthew Watson

MILAN, Italy and NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announces that Richard Slansky is appointed as Chief Financial Officer (“CFO”) and proposes Anthony Marucci as independent member of the Board of Directors. The news follows the announcement of Stephen Squinto, PhD, as Chairman last November. Both Board appointments will be effective following their approval at the Genenta Shareholders’ Meeting on May 20, 2021.

See the rest here:
Genenta to Appoint Richard Slansky as CFO and Anthony Marucci as Board Member

Related Post


categoriaGlobal News Feed commentoComments Off on Genenta to Appoint Richard Slansky as CFO and Anthony Marucci as Board Member | dataMay 3rd, 2021

About...

This author published 3792 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research